Alphatec Holdings, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US02081G2012
USD
21.28
0.11 (0.52%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Alphatec Holdings, Inc. stock-summary
stock-summary
Alphatec Holdings, Inc.
Pharmaceuticals & Biotechnology
Alphatec Holdings, Inc. is a medical technology company. The Company through its subsidiary, Alphatec Spine, Inc. and its subsidiaries, designs, develops, manufactures and markets products for the surgical treatment of spine disorders. Its product portfolio and pipeline addresses the cervical, thoracolumbar and intervertebral regions of the spine and covers a range of spinal disorders and surgical procedures. Its products include Cervical and Cervico-Thoracic Products, which include Trestle Luxe Anterior Cervical Plate System and Pegasus Anchored Cervical Interbody; Thoracolumbar Fixation Products, which include Arsenal Degenerative System and OsseoScrew Spinal Fixation System; Spinal Spacers, which include Battalion Universal Spacer System and Alphatec Solus Locking ALIF Spinal Spacer; minimally invasive surgery Products, which include Illico Minimally Invasive Surgery System and BridgePoint Spinous Process Fixation System, and Biologics, which include Neocore Osteoconductive Matrix.
Company Coordinates stock-summary
Company Details
5818 El Camino Real , CARLSBAD CA : 92008
stock-summary
Tel: 1 760 43192861 760 4946790
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 61 Schemes (22.61%)

Foreign Institutions

Held by 95 Foreign Institutions (10.21%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Patrick Miles
Chairman of the Board, President, Chief Executive Officer
Mr. Mortimer Berkowitz
Lead Independent Director
David Pelizzon
Director
Mr. Jeffrey Rydin
Director
Mr. Evan Bakst
Independent Director
Mr. Quentin Blackford
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
186 Million
(Quarterly Results - Jun 2025)
Net Profit:
-41 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 2,448 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

8.51

stock-summary
Return on Equity

-272.15%

stock-summary
Price to Book

51.67